AbbVie and MBC BioLabs invite you to apply for the 2019 AbbVie Golden Ticket!
AbbVie and MBC BioLabs invite entrepreneurial scientists and founders to apply for a 2019 AbbVie Golden Ticket. The AbbVie Golden Ticket provides a year's use of a lab bench and core facilities at MBC BioLabs' San Francisco or San Carlos site, as well as opportunities to engage with AbbVie scientific and business leaders. It will be awarded to an early stage company developing novel, transformational therapies for autoimmune, oncology, or neurodegenerative disease.
To apply, please email your non-confidential company presentation to GoldenTicket@abbvie.comby Friday, February 1, 2019.
In the application, please address:
What is the scientific insight and approach driving your company?
If successful, how would your therapeutic approach provide significant patient benefit beyond currently available treatment or other R&D stage programs?
Selected applicants will be invited to present their company to a select group of AbbVie leadership at an event to be held at MBC BioLabs in March.
Beyond Next Ventures and MBC BioLabs invite you to explore the latest in Japanese life science innovation on January 10th, when seven startups specially selected for the Tokyo prefectural government's Blockbuster TOKYO initiative will pitch at MBC BioLabs San Francisco. The pitches will be followed by a networking reception, and the event will provide a unique opportunity to learn about and access Japan's burgeoning bioventure ecosystem.
January 10, 2019
2:30 to 4:30 PM Networking Reception to Follow
953 Indiana Street, San Francisco
Beyond Next Venturesis a seed/early-stage Tokyo-based venture capital firm focusing on medtech and life science. Their first fund was established in 2015, with US $55 million in committed as the lead investor in 23 companies. Their second fund of US $100 million was established in October 2018. They also serve as a certified venture capital firm for Japanese government-associated organizations such as the New Energy and Industrial Technology Development Organization and the Program for Start-ups from Advanced Research & Technology. They also operate BRAVE, Japan's largest university startup accelerator, and have been exclusively tasked by the Tokyo Prefectural Government with operating the Blockbuster TOKYO accelerator for drug discovery startups. Finally, their Innovation Leaders Program gives employees of large corporations the opportunity to extern/embed at startups, and in February 2018 they established a wet lab laboratory space in Tokyo to support and advance the local biotech ecosystem.
AesculaTech engages in the development of smart materials for medical devices. Our first product is a treatment for the millions of Americans in the US that suffer from dry eye syndrome. The device is one-size-fits-all and easy to administer, resulting in improved patient comfort, better outcomes and fewer repeat procedures.
CellFE (Cell Fluidics Engineering) brings innovative technology to engineer the next generation of cell therapies to fight cancer and other challenging diseases. CellFE has developed a unique microfluidic platform to solve one of the most pressing issues of therapeutic cell engineering - how to efficiently deliver gene-editing molecules into cells while preserving cell viability.
CuraSen Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative diseases, including Parkinson's Disease, Alzheimer's Disease and less common neurodegenerative disorders. The company is developing small molecule drugs targeting a novel mechanism in the brain to modify disease pathology, and alleviate disabling symptoms, such as cognition, executive function, and motor and autonomic dysfunction, all of which can severely impact quality of life. CuraSen's drugs are designed to activate certain receptor populations in the brain to compensate for critical neuronal and glial functions that have otherwise been lost due to degeneration.
Gordian is pioneering unbiased, high throughput, in vivo screening to radically increase the efficiency of therapeutic development for complex diseases of aging.